Integrative Physiology/Experimental Medicine Therapeutic Neovascularization by Nanotechnology- Mediated Cell-Selective Delivery of Pitavastatin Into the Vascular Endothelium

Objective—Recent clinical studies of therapeutic neovascularization using angiogenic growth factors demonstrated smaller therapeutic effects than those reported in animal experiments. We hypothesized that nanoparticle (NP)-mediated cell-selective delivery of statins to vascular endothelium would more effectively and integratively induce therapeutic neovascularization. Methods and Results—In a murine hindlimb ischemia model, intramuscular injection of biodegradable polymeric NP resulted in cell-selective delivery of NP into the capillary and arteriolar endothelium of ischemic muscles for up to 2 weeks postinjection. NP-mediated statin delivery significantly enhanced recovery of blood perfusion to the ischemic limb, increased angiogenesis and arteriogenesis, and promoted expression of the protein kinase Akt, endothelial nitric oxide synthase (eNOS), and angiogenic growth factors. These effects were blocked in mice administered a nitric oxide synthase inhibitor, or in eNOS-deficient mice. Conclusions—NP-mediated cell-selective statin delivery may be a more effective and integrative strategy for therapeutic neovascularization in patients with severe organ ischemia. (Arterioscler Thromb Vasc Biol. 2009;29:796-801.)

[1]  Y. Tabata,et al.  A novel approach to therapeutic angiogenesis for patients with critical limb ischemia by sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel: an initial report of the phase I-IIa study. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[2]  T. Fujii,et al.  Nonendothelial Mesenchymal Cell–Derived MCP-1 Is Required for FGF-2–Mediated Therapeutic Neovascularization: Critical Role of the Inflammatory/Arteriogenic Pathway , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[3]  K. Sunagawa,et al.  Essential Role of Vascular Endothelial Growth Factor and Flt-1 Signals in Neointimal Formation After Periadventitial Injury , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[4]  K. Sunagawa,et al.  Blockade of Vascular Endothelial Growth Factor Suppresses Experimental Restenosis After Intraluminal Injury by Inhibiting Recruitment of Monocyte Lineage Cells , 2004, Circulation.

[5]  W. Schaper,et al.  Influence of Mechanical, Cellular, and Molecular Factors on Collateral Artery Growth (Arteriogenesis) , 2004, Circulation research.

[6]  K. Egashira,et al.  Cholesterol-Lowering Independent Regression and Stabilization of Atherosclerotic Lesions by Pravastatin and by Antimonocyte Chemoattractant Protein-1 Therapy in Nonhuman Primates , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[7]  Stefanie Dimmeler,et al.  Therapeutic angiogenesis and vasculogenesis for ischemic disease: part II: cell-based therapies. , 2004, Circulation.

[8]  Stefanie Dimmeler,et al.  Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: angiogenic cytokines. , 2004, Circulation.

[9]  H. Nishimatsu,et al.  Statins Augment Collateral Growth in Response to Ischemia but They Do Not Promote Cancer and Atherosclerosis , 2004, HYPERTENSION.

[10]  A. Takeshita,et al.  Gene Transfer of Stromal Cell–Derived Factor-1&agr; Enhances Ischemic Vasculogenesis and Angiogenesis via Vascular Endothelial Growth Factor/Endothelial Nitric Oxide Synthase–Related Pathway: Next-Generation Chemokine Therapy for Therapeutic Neovascularization , 2004, Circulation.

[11]  W. Schaper,et al.  Factors Regulating Arteriogenesis , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[12]  A. Zeiher,et al.  Double-Edged Role of Statins in Angiogenesis Signaling , 2002, Circulation research.

[13]  M. Shibuya,et al.  Vascular Endothelial Growth Factor Is Necessary in the Development of Arteriosclerosis by Recruiting/Activating Monocytes in a Rat Model of Long-Term Inhibition of Nitric Oxide Synthesis , 2002, Circulation.

[14]  V. Labhasetwar,et al.  Characterization of nanoparticle uptake by endothelial cells. , 2002, International journal of pharmaceutics.

[15]  J. Liao,et al.  Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[16]  H. Nishimatsu,et al.  Endothelial nitric oxide synthase is essential for the HMG‐CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  C. Kataoka,et al.  Antiinflammatory and Antiarteriosclerotic Actions of HMG-CoA Reductase Inhibitors in a Rat Model of Chronic Inhibition of Nitric Oxide Synthesis , 2001, Circulation research.

[18]  D. Altieri,et al.  Statins' benefits begin to sprout. , 2001, The Journal of clinical investigation.

[19]  A M Zeiher,et al.  HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. , 2001, The Journal of clinical investigation.

[20]  J. Isner,et al.  HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. , 2001, The Journal of clinical investigation.

[21]  M. Dake,et al.  Vascular endothelial growth factor enhances atherosclerotic plaque progression , 2001, Nature Medicine.

[22]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[23]  I. Shiojima,et al.  The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. , 2000, Nature Medicine.

[24]  Napoleone Ferrara,et al.  Clinical applications of angiogenic growth factors and their inhibitors , 1999, Nature Medicine.

[25]  Y. Kawashima,et al.  Properties of a peptide containing DL-lactide/glycolide copolymer nanospheres prepared by novel emulsion solvent diffusion methods. , 1999, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[26]  K Walsh,et al.  Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. , 1998, Circulation.

[27]  R. Morishita,et al.  Characterization of in vivo gene transfer into the arterial wall mediated by the Sendai virus (hemagglutinating virus of Japan) liposomes: an effective tool for the in vivo study of arterial diseases. , 1996, Laboratory investigation; a journal of technical methods and pathology.